About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« GSK to Acquire Reliant Pharmaceuticals | Main | InterMune Buys out License Agreement for Pirfenidone »

November 28, 2007

Astellas to Acquire Agensys,Inc.

    By Sherri Oslick --

Astellas Astellas Pharma Inc. of Tokyo, has announced an agreement between its U.S. subsidiary, Astellas U.S. Holding of Deerfield, IL and Agensys, Inc. of Santa Monica CA under which Astellas will acquire Agensys for $387 million in cash, with up to an additional $150 million dependent upon Agensys' achievement of various milestones.  Agensys is a privately held biotechnology company focused on therapeutic antibody research and development in the area of cancer.

Agensys Agensys' portfolio includes 30 proprietary cancer targets to 14 different tumor types, and an antibody targeting prostate, pancreatic, and bladder cancers in Phase Ib clinical trials, and several candidate antibodies in the late preclinical stage.  Agensys develops human monoclonal antibodies through the use XenoMouse®, a human antibody-producing transgenic mouse in-licensed from Abgenix.  Agensys' patent portfolio includes over 100 issued patent or allowed applications and over 300 pending patent applications.

For additional information regarding Astellas' sacquisition of Agensy, please see:

Posted at 10:53 PM in Licensing |

Comments

The comments to this entry are closed.

November 2024

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Categories

Archives

More...